Skip to main content

Human Papillomavirus clinical trials at UCSF
6 in progress, 3 open to new patients

  • Phase Ib Study of Alpelisib With Cisplatin in Patients With HPV+ Solid Tumor Malignancies

    open to eligible people ages 18 years and up

    This is a Phase Ib dose escalation / expansion study with the combination of alpelisib and weekly cisplatin. Dose escalation will follow standard 3+3 design. During dose escalation, two dose levels of weekly cisplatin (30 and 35 mg/m2, respectively) will be evaluated in combination with escalating doses of alpelisib in parallel. Cohort B (cisplatin 35 mg/m2) at a given dose level of alpelisib to open only after corresponding A cohort (cisplatin 30 mg/m2) at the same dose level of alpelisib has cleared DLT window. Cohorts A and B may enroll in parallel (e.g., Cohort 3A may enroll in parallel with Cohort 2B) as shown below in the dose escalation schema. Intermediate dose levels and alternative dosing schedules may be investigated per the discretion of Principal Investigator using same 3+3 dose escalation schema (e.g. cisplatin administered days 1, 8 of 21 day cycle).

    San Francisco, California

  • Recombinant Human Papillomavirus Nonavalent Vaccine in Preventing Human Papillomavirus-Related Cancer in Adult Women After Kidney Transplant

    open to eligible females ages 18–49

    This phase II trial studies how well recombinant human papillomavirus nonavalent vaccine works in preventing human papillomavirus-related cancer in adult women after kidney transplant. Vaccines made from peptides of human papillomavirus may help the body build an effective immune response to kill tumor cells. Giving booster vaccinations may make a stronger immune response and prevent or delay the recurrence of cancer.

    San Francisco, California and other locations

  • Topical or Ablative Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Squamous Intraepithelial Lesions

    open to eligible people ages 35 years and up

    This randomized phase III trial compares topical or ablative treatment with active monitoring in preventing anal cancer in patients with human immunodeficiency virus (HIV) and high-grade squamous intraepithelial lesions (HSIL). Anal HSIL is tissue in the anal canal that has been damaged by infection with human papillomavirus (HPV) and is at risk for turning into anal cancer. It is not yet known if treating HSIL is more effective than active monitoring in preventing patients from developing anal cancer.

    San Francisco, California and other locations

  • Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer

    Sorry, in progress, not accepting new patients

    This randomized phase II trial studies how well transoral surgery followed by low-dose or standard-dose radiation therapy works in treating patients with human papilloma virus (HPV) positive stage III-IVA oropharyngeal cancer. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving radiation therapy with chemotherapy may kill any tumor cells that remain after surgery. It is not yet known how much extra treatment needs to be given after surgery.

    San Francisco, California and other locations

  • TRYHARD: Radiation Therapy Plus Cisplatin With or Without Lapatinib in Treating Patients With Head and Neck Cancer.

    Sorry, in progress, not accepting new patients

    PURPOSE: This trial is studying if and how well lapatinib adds to the effectiveness of radiation therapy plus cisplatin in patients who have head and neck cancer that is not related to the HPV virus.

    San Francisco, California and other locations

  • Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males

    Sorry, in progress, not accepting new patients

    RATIONALE: Vaccines made from a gene-modified virus may help the body build an effective immune response to prevent viral infection.

    PURPOSE: This phase II trial is studying how well vaccine therapy works in preventing human papillomavirus (HPV) infection in young HIV-positive male patients who have sex with males.

    San Francisco, California and other locations